Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

The Center in Asbury Park wants people to "Come Early, Stand Proud, and Walk Strong" on May 4 for the New Jersey AIDS Walk ...

“Trump ’47 should not allow Trump ’45’s massive public health achievement to be cancelled — especially when that legacy will ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

A new report shows a sharp rise in STIs in Houston and Harris County, with the city's rates now exceeding statewide averages ...

A modeling study looked at how anticipated cuts to international HIV funding would affect the rate of new cases and ...

Serhat Gumrukcu, 42, hired Jerry Banks through two associates to murder Gregory Davis in 2018, in Vermont, U.S. Attorney's ...

The Trump Administration has gutted many areas of healthcare funding and research, especially in infectious diseases. One ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Long-acting injectable HIV treatment leads to rectal shedding in a small proportion of patients with HIV, independent of the ...

Hepatitis, HIV, tuberculosis (TB) and sexually transmitted infections such as syphilis and gonorrhoea continue to pose ...